MRNA Begins Dosing in Pivotal Study on Norovirus Vaccine [Yahoo! Finance]
ANI Pharmaceuticals, Inc. (ANIP)
Last ani pharmaceuticals, inc. earnings: 2/27 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
anipharmaceuticals.com/investors_corporate_profile.php
Company Research
Source: Yahoo! Finance
MRNA announced the dosing of the first participant in the phase III Nova 301 study, which is evaluating its investigational mRNA norovirus vaccine candidate, mRNA-1403, in the United States. The randomized, placebo-controlled phase III study will evaluate the safety, efficacy and immunogenicity of mRNA-1403 to prevent moderate-to-severe acute gastroenteritis caused by norovirus. Recruitment of participants in the pivotal Nova 301 study across the world has also begun. Shares of Moderna have plunged 32.8% so far this year compared with the industry's decline of 1.8%. Image Source: Zacks Investment Research More on MRNA's Norovirus Vaccine Study The company is looking to enroll around 25,000 participants aged 18 years and above in the phase III Nova 301 study worldwide. The study will enroll around 20,000 participants aged 60 years and older and 5,000 participants aged between 18 and 59 years. The study will investigate the ability of mRNA-1403 to protect against moderat
Show less
Read more
Impact Snapshot
Event Time:
ANIP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIP alerts
High impacting ANI Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ANIP
News
- Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? [Yahoo! Finance]Yahoo! Finance
- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $94.00 price target on the stock.MarketBeat
- ANI Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics [Yahoo! Finance]Yahoo! Finance
- ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance [Yahoo! Finance]Yahoo! Finance
ANIP
Earnings
- 11/8/24 - Beat
ANIP
Sec Filings
- 11/20/24 - Form 8-K
- 11/18/24 - Form 4
- 11/18/24 - Form 4
- ANIP's page on the SEC website